Venetoclax in Combination with Daratumumab for Multiple Myeloma Treatment

A 60-year-old White woman, with a history of heavy smoking, was diagnosed with stage II multiple myeloma. Cytogenetics showed gain(1q21) and her ECOG performance score was 0. At the time, she was treated with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) induction therapy, followed by autologous stem cell transplant. She achieved a complete remission with VRd and transplant and was also minimal residual disease (MRD) negative. The patient was then placed on lenalidomide maintenance therapy.

Ciltacabtagene autoleucel was recently said to be a new standard-of-care for relapsed or refractory multiple myeloma. Soon, it may be an FDA-approved therapy.

According to Binod Dhakal, MD, ciltacabtagene autoleucel may become a new standard therapy for patients with lenalidomide (Revlimid)-refractory multiple myeloma.

Promising results reported from a study of GC012F in patients with relapsed or refractory multiple myeloma, warrant further research.

Pooled findings from MagnetisMM studies show the elranatamab has early activity in relapsed or refractory multiple myeloma.

MD Anderson Cancer Center's Hans C. Lee, MD has presented promising results from the phase 2 LINKER-MM1 study at ASCO.